Source: 24/7 News
(New York, NY) -- The FDA is approving a breakthrough cancer drug that could have a major impact on how doctors treat more than a dozen cancers.
Dr. David Hyman, of Memorial Sloan Kettering in New York City, lead the research on the new drug called Larotrectinib [[ Larrow-trect-tin-nib ]].
Dr. Hyman said patients saw tumors disappear often within days.
He adds the new drug is based on genetics, including 17 different malignancies which includes lung and breast cancers.